Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders

By R. Rupprecht, V. Papadopoulos, G. Rammes, T. Baghai, Jinjiang Fan, N. Akula, Ghislaine Groyer, David Adams, M. Schumacher. Nature reviews. Drug discovery, 2010

902 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Molecular Biology, Pediatrics, Perinatology and Child Health

View Paper: https://www.semanticscholar.org/paper/a63d42206ea2e24d03fdc086e37beaaa83458d7a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. C. Nemeroff
2. R. Yirmiya

In Molecular Biology

1. C. Nemeroff
2. Eléonore Beurel
3. R. Yirmiya

In Pediatrics, Perinatology and Child Health

1. C. Nemeroff
2. R. Yirmiya

Citations in the corpus

• The Bidirectional Relationship of Depression and Inflammation: Double Trouble (2020, background): “Indeed, expression level of the translocator protein (TSPO), analyzed by PET scans using TSPO ligands, is low in the healthy brain and is upregulated locally during neuropathological conditions, and has been therefore used to measure neuroinflammation (Rupprecht et al., 2010).”
• Depression as a microglial disease. (2015, background): “Expression levels are low in the healthy brain, but are markedly upregulated locally during neuropathological conditions, providing the rational for assessing the binding of labeled TSPO ligands by PET imaging techniques to visualize and quantitate various neuroinflammatory conditions [36].”
• Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023, background): “128,11 [C](R)-PK11195 (PK), as the fi rst-generation TSPO PET tracer, has been extensively used to study microglial activation.”